Lataa...
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, DNA damage repair, and synthetic lethality. We disc...
Tallennettuna:
| Julkaisussa: | Cancers (Basel) |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7465003/ https://ncbi.nlm.nih.gov/pubmed/32722408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082054 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|